My watch list  

Aureus Pharma extends collaboration with Sanofi-Aventis


Aureus Pharma, a provider of knowledge management solutions to aid discovery in the life sciences industry, announced that sanofi-aventis has become its first customer for the company's recently released AurSCOPE® Ion Channel database. This agreement extends the collaboration between Aureus Pharma and sanofi-aventis which already covered other Aureus databases. The financial terms of the agreement were not disclosed.

This new database gives researchers access to information on all major ion channels already described in scientific literature, allowing the identification, validation and prioritization of new targets and ligands for drug discovery. Sanofi-aventis plans to use the AurSCOPE-Ion Channel database to help researchers speed up its discovery process in a number of fields.

The agreement means that Aureus Pharma is successfully expanding its range of knowledge management tools, and increasing market penetration. The company already has collaboration agreements with other life science companies including Roche.

The market importance of ion channels as a class of targets for drug discovery is growing. They play a crucial role in all functions in the human body and are targets in a wide variety of diseases including cystic fibrosis, epilepsy and arrhythmia. They remain one of the less exploited therapeutic target areas studied today, one of the reasons why Aureus Pharma has developed its AurSCOPE to accelerate research in this field.

Facts, background information, dossiers
  • Sanofi-aventis
  • ion channels
  • Aureus Pharma
More about Sanofi-Aventis
More about Aureus Pharma
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE